| Karl Machata, MD | |
|
455 Toll Gate Rd, Warwick, RI 02886-2759 | |
| (508) 675-6591 | |
| (508) 675-7905 |
| Full Name | Karl Machata |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 455 Toll Gate Rd, Warwick, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114995115 | NPI | - | NPPES |
| 9001782 | Medicaid | RI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD05868 (Rhode Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Karl Machata, MD 275 Martine St, Suite # 301, Fall River, MA 02723-1516 Ph: (508) 675-6591 | Karl Machata, MD 455 Toll Gate Rd, Warwick, RI 02886-2759 Ph: (508) 675-6591 |
News Archive
To determine how arsenic increases the risk of lung cancer and to identify potential treatments, a Michigan State University researcher will use $1.7 million in federal funding during the next five years to examine why certain genes disrupt cells, leading to the disease.
Scientists have long known that therapies that target the cancer-driving MAPK pathway are only effective in a handful of cancers with specific mutations in a cancer gene called BRAF, and these cancers that initially respond to the therapy often end up developing resistance to the treatment, resulting in relapse for many patients.
Individual neurons can learn not only single responses to a particular signal, but also a series of reactions at precisely timed intervals. This is what emerges from a study at Lund University in Sweden.
New research from Mount Sinai School of Medicine sheds light on how overeating can cause a malfunction in brain insulin signaling, and lead to obesity and diabetes. Christoph Buettner, MD, PhD, Associate Professor of Medicine (Endocrinology, Diabetes and Bone Disease) and his research team found that overeating impairs the ability of brain insulin to suppress the breakdown of fat in adipose tissue.
Protalix BioTherapeutics, Inc. announced today that it has initiated a phase I clinical trial of PRX-105, the Company's plant cell expressed pegylated recombinant human acetylcholinesterase product candidate in development for biodefense indications. The trial is designed to study the safety of PRX-105 by administering a bolus intravenous injection of PRX-105 in healthy volunteers.
› Verified 9 days ago
Christopher Baze, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 455 Toll Gate Rd, Warwick, RI 02886 Phone: 401-737-7010 | |
Kenneth Robert Larsen, D.O Emergency Medicine Medicare: Medicare Enrolled Practice Location: 455 Toll Gate Rd, Warwick, RI 02886 Phone: 401-736-4289 | |
Lindsey Gori, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 455 Toll Gate Rd, Warwick, RI 02886 Phone: 401-737-7010 | |
Ashley Mildred Langella, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 455 Toll Gate Rd, Office Of Graduate Medical Education, Warwick, RI 02886 Phone: 401-731-7000 | |
Jonathan Trent Vanadore, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 455 Toll Gate Rd, Warwick, RI 02886 Phone: 401-737-7010 | |
Stephanie Leigh Aaron, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 455 Toll Gate Road, Warwick, RI 02886 Phone: 864-650-2955 | |
Catherine Spallina, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 455 Toll Gate Rd, Warwick, RI 02886 Phone: 401-737-7010 |